| Literature DB >> 26140904 |
Renata Fortes Santiago1, Tarcisio Vieira de Brito1, Jordana Maia Dias1, Genilson José Dias1, José Simião da Cruz1, Jalles Arruda Batista1, Renan Oliveira Silva2, Marcellus H L P Souza2, Ronaldo de Albuquerque Ribeiro2, Stanley Juan Chavez Gutierrez3, Rivelilson M Freitas4, Jand-Venes R Medeiros1, André Luiz Dos Reis Barbosa5.
Abstract
The aim of our study was to evaluate the anti-inflammatory, anti-nociceptive, and anti-oxidant action of Riparin B in vivo. We performed experiments in which we induced paw edema by carrageenan and other mediators, carrageenan-induced peritonitis and the level of myeloperoxidase (MPO) activity, pro-inflammatory cytokines (TNF-α and IL-1β), malondialdehyde (MDA) acid, and glutathione (GSH) from the peritoneal fluid. We also performed behavior tests such as acetic acid-induced writhing, formalin-induced linking, and the hot plate test. Among the doses tested of the Riparin B (1, 3, and 10 mg/kg), the dose of 10 mg/kg showed the strongest effect, and this dose was able to reduce the paw edema induced by carrageenan, dextran, histamine serotonin, bradykinin, 48/80, and PGE2. Similarly, the Riparin B in the same dose reduced cell migration and significantly decreased the nociception induced by formalin and acetic acid and reversed the parameters of the oxidative stress. Thus, we can infer that Riparin B exhibits anti-inflammatory, anti-nociceptive, and anti-oxidant actions in vivo.Entities:
Keywords: Riparin; anti-inflammatory; anti-nociceptive; anti-oxidant
Mesh:
Substances:
Year: 2015 PMID: 26140904 DOI: 10.1007/s10753-015-0203-4
Source DB: PubMed Journal: Inflammation ISSN: 0360-3997 Impact factor: 4.092